Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Abstract Objective: To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of venous thromboembolism. Design: Matched case-control study. Setting: 10 centres in Germany and United Kingdom. Subjects: Cases were 471 women aged 16-44 who had a venous thromboembolism. Controls were 1772 women (at least 3 controls per case) unaffected by venous thromboembolism who were matched with corresponding case for age and for hospital or community setting. Main outcome measures: Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. Results: Odds ratios (95% confidence intervals) for venous thromboembolism were: for any oral contraceptives versus no use, 4.0 (3.1 to 5.3); for second generation products (low dose ethinyloestradiol, no gestodene or desogestrel) versus no use, 3.2 (2.3 to 4.3); for third generation products (low dose ethinyloestradiol, gestodene or desogestrel) versus no use, 4.8 (3.4 to 6.7); for third generation products versus second generation products, 1.5 (1.1 to 2.1); for products containing gestodene versus second generation products, 1.5 (1.0 to 2.2); and for products containing desogestrel versus second generation products, 1.5 (1.1 to 2.2). Probability of death due to venous thromboembolism for women using third generation products is about 20 per million users per year, for women using second generation products it is about 14 per million users per year, and for non-users it is five per million per year. Conclusions: Risk of venous thromboembolism was slightly increased in users of third generation oral contraceptives compared with users of second generation products. Key messages Key messages This case-control study examined risk of venous thromboembolism associated with different types of oral contraceptive Overall, there was a fourfold higher relative risk of thromboembolism associated with current use of any oral contraceptive versus no current use The risk of thromboembolism was 1.5 times higher for third generation contraceptives compared with second generation products Our data indicate the need for clinical prudence but allow doctors and women seeking contraception to exercise informed choice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROPORTION OF DISEASE CAUSED OR PREVENTED BY A GIVEN EXPOSURE, TRAIT OR INTERVENTION1
MIETTINEN, O. S. (1974) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a121617 · Cited by 1,036
The occurrence of lung cancer in man.
Ml, L. (1953) · PubMed · Cited by 981
Oral Contraceptives and Cardiovascular Disease
Stadel, B. V. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109103051104 · Cited by 494
Attributable risk percent in case-control studies.
Cole, P., & MacMahon, B. (1971) · Journal of Epidemiology & Community Health · doi:10.1136/jech.25.4.242 · Cited by 342
Jung-Hoffmann, C., & Kühl, H. (1989) · Contraception · doi:10.1016/0010-7824(89)90094-2 · Cited by 83
Kühl, H., Jung-Hoffmann, C., & Heidt, F. (1988) · Contraception · doi:10.1016/0010-7824(88)90088-1 · Cited by 58
Oral contraceptives and cardiovascular disease: An epidemiologic overview
Thorogood, M. (1993) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2630020103 · Cited by 26
Self-citationAdvances in Oral Contraception
Hickey, M. J., & Levin, J. H. (1993) · Springer eBooks · doi:10.1007/978-1-4612-4340-3_12 · Cited by 2
Cited by
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard, O., Lokkegaard, E., Svendsen, A. L., & Agger, C. (2009) · BMJ · doi:10.1136/bmj.b2890 · Cited by 709
Guidelines on diagnosis and management of acute pulmonary embolism
(2000) · European Heart Journal · doi:10.1053/euhj.2000.2250 · Cited by 645
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 623
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Oral Contraceptives and the Risk of Venous Thrombosis
Vandenbroucke, J. P., Rosing, J., Bloemenkamp, K. W. M., Middeldorp, S., Helmerhorst, F. M., Bouma, B. N., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442007 · Cited by 579
Dinger, J. C., Heinemann, L. A. J., & Kühl-Habich, D. (2007) · Contraception · doi:10.1016/j.contraception.2006.12.019 · Cited by 470
Self-citationThird generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren, J. M., Algra, A., & Grobbee, D. E. (2001) · BMJ · doi:10.1136/bmj.323.7305.131 · Cited by 455
Risk factors for venous and arterial thrombosis.
Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011) · PubMed · doi:10.2450/2010.0066-10 · Cited by 447
Ischemic Stroke Risk With Oral Contraceptives: A Meta-analysis
Gillum, L. A., Mamidipudi, S. K., & Johnston, S. C. (2000) · JAMA · doi:10.1001/jama.284.1.72 · Cited by 402
Risk Factors for Venous Thrombotic Disease
Rosendaal, F. R. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615887 · Cited by 375
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Oral contraceptives and venous thromboembolism: a five-year national case-control study☆
Lidegaard, Ø., Edström, B., & Kreiner, S. (2002) · Contraception · doi:10.1016/s0010-7824(01)00307-9 · Cited by 334
Population-based study of risk of venous thromboembolism associated with various oral contraceptives
Farmer, R., Lawrenson, R., Thompson, C., Kennedy, J., & Hambleton, I. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07496-x · Cited by 329
Thrombosis in the Young: Epidemiology and Risk Factors. A Focus on Venous Thrombosis
Rosendaal, F. R. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657492 · Cited by 327
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2012) · BMJ · doi:10.1136/bmj.e2990 · Cited by 326
Rosing, J., Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Van Oerle, R., Van DerPloeg, P. M. E. N., Heijnen, P., Hamulyak, K., & Hemker, H. C. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.192707.x · Cited by 325
“…fact that, compared with non-carriers non-users, the increased risk for deep-vein thrombosis of non-carriers who use third-generation OC (7–8-fold) (Spitzer et al, 1996; W.H.O., 1995a, b) is similar to that of heterozygous carriers not using OC (7-fold) (Koster et al, 1993), and that heterozygous…”
BackgroundRisk factors for venous thromboembolism
Heit, J. A. (2003) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(02)00077-1 · Cited by 294
Risk Factors in Venous Thromboembolism
Martinelli, I. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616237 · Cited by 291
Progestin-only contraception and thromboembolism: A systematic review
Tepper, N. K., Whiteman, M. K., Marchbanks, P. A., James, A. H., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.04.014 · Cited by 272
Female Hormones and Thrombosis
Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0202.102318 · Cited by 267
(1998) · Contraception · doi:10.1016/s0010-7824(98)00041-9 · Cited by 259
Rosing, J., Middeldorp, S., Curvers, J., Thomassen, M. C. L. G., Nicolaes, G. A., Meijers, J. C., Bouma, B. N., Büller, H. R., Prins, M. H., & Tans, G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06092-4 · Cited by 257
Dragoman, M. V., Tepper, N. K., Fu, R., Curtis, K. M., Chou, R., & Gaffield, M. E. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12455 · Cited by 253
Martinelli, I., Lensing, A. W. A., Middeldorp, S., Levi, M., Beyer-Westendorf, J., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Trajanovic, M., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665927 · Cited by 219
Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.49 · Cited by 213
Tans, G., Curvers, J., Middeldorp, S., Thomassen, M. C., Prins, M., Bouma, B., Büller, H., Meijers, J., & Rosing, J. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613960 · Cited by 203
“The discussion about the mechanistic basis of OC-associated venous thrombosis became an issue again in 1995 when it was reported that women who use OC with so-called third generation progestagens (desogestrel or gestodene) have an approximately 2-fold higher risk of VTE than women who use the older second generation O…”
BackgroundValidation of the diagnosis of venous thromboembolism in general practice database studies
Lawrenson, R., Todd, J. ‐., Leydon, G. M., Williams, T. J., & Farmer, R. D. T. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00199.x · Cited by 180
Kemmeren, J. M., Algra, A., Meijers, J. C. M., Tans, G., Bouma, B. N., Curvers, J., Rosing, J., & Grobbee, D. E. (2004) · Blood · doi:10.1182/blood-2003-04-1285 · Cited by 157
Gronich, N., Lavi, I., & Rennert, G. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110463 · Cited by 135
Ågren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M.-L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.604450 · Cited by 130
Safety of medical treatments for endometriosis
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1121991 · Cited by 78
Gomes, M. P. V., & Deitcher, S. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.1965 · Cited by 44
A current perspective into young female sex hormone replacement: a review
Giordano Imbroll, M., & Gruppetta, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1816820 · Cited by 7
The 1995 Pill scare and its aftermath: lessons learnt
BHATHENA, R. K. (1998) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443619867335 · Cited by 6
Metadata
- Authors
- Spitzer, W. O., Lewis, M. A., Heinemann, L. A. J., Thorogood, M., & MacRae, K. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1996-01-13
- Volume
- 312
- Issue
- 7023
- Pages
- 83-88
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1979306178
- Cited by
- 594
- References
- 8
- FWCI
- 41.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.